Quality of life assessments have become especially important to those designing medicines to treat the ill. Developing drugs free of troublesome side effects is a major priority for pharmaceutical companies. Assessing and analyzing quality of life data is quickly becoming part of clinical trials procedure, and is even mandatory for acquiring major research grants. Written by two pioneers in the quality of life field, this is the first book to detail extensively the guidelines for assessing and analyzing quality of life data.
Peter Fayers